SCHEMBL206675

SCHEMBL206675

Fc1ccc(-c2csc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 11/20 0.58
MAPT P10636 4/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
RAB9A P51151 2/20 0.57
NPY5R Q15761 1/20 0.57
NPC1 O15118 1/20 0.57
POLB P06746 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
VCP P55072 3/20 0.57
CFTR P13569 1/20 0.54
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
MAPK1 P28482 2/20 0.53
CYP1B1 Q16678 1/20 0.50
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
LMNA P02545 1/20 0.49
HPGD P15428 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207226 0.92 ALOX5 (0.70) ALOX5MAPTTDP1VCPMEN1
SCHEMBL206148 0.89 ALOX5 (0.66) ALOX5MAPTPOLBTDP1VCP
SCHEMBL12297925 0.86 ALOX5 (0.54) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL205448 0.86 ALOX5 (0.65) ALOX5MAPTSMN1; SMN2RAB9ANPY5R
SCHEMBL208205 0.85 AGER (0.59) ALOX5MAPTRAB9ANPC1VCP
SCHEMBL12297192 0.83 ALOX5 (0.65) ALOX5MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL12297956 0.82 ALOX5 (0.69) ALOX5MAPTSMN1; SMN2VCPMEN1
SCHEMBL207250 0.82 MEN1 (0.68) MAPTSMN1; SMN2RAB9ANPC1TDP1
SCHEMBL12297797 0.81 ALOX5 (0.54) ALOX5MAPTSMN1; SMN2VCPMEN1
SCHEMBL7112167 0.81 ALOX5 (0.75) ALOX5MAPTSMN1; SMN2NPY5RTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-8088806-B2 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. (US) 2012-01-03 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed
US-20070004711-A1 Thiazole compounds and methods of use ACHILLION PHARMACEUTICALS, INC. 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108576-A1 THIAZOLE COMPOUNDS AND METHODS OF USE PIGS, CPT1A, SLC10A1 ALOX5 3410/4885MAPT 2207/4885SMN1; SMN2 3252/4885
US-20070004711-A1 Thiazole compounds and methods of use PIGS, CPT1A, SLC10A1 ALOX5 3410/4885MAPT 2207/4885SMN1; SMN2 3252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.